Zuckerberg has META firing on all cylinders 🧨

Plus check out today’s other big movers                                                                                                                                                                                                                                                                                                                                                                                                                 July 27, 2023 | [Read Online]( Good day, 360 – Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street! LCPN - Up over 40% in pre-market after phase 2 study meets primary endpoint in patients with Cirrhosis MNK - Closed up 186% after sources said company considering Bankruptcy as part of plan to avoid paying money it owes to opioid victims META - Up 8% in pre after beating earnings estimates and growing ad revenue 💥TODAY, THURSDAY, 1PM ET💥 Jason Wants More. Think His Small Account Journey Trading Is Impressive? You Wait Till Jason Turns Up The Heat With… The Trading Education Goal Is Straightforward. Strike Your Target. Extract Your Capital. Jason’s Prepared To Teach You How He’s Doing This! ➡️ [1PM ET → COMPLIMENTARY!]( ⬅️ LCPN - Up over 40% in pre-market after phase 2 study meets primary endpoint in patients with Cirrhosis Lipocine Inc (LPCN), a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. This morning, the [company announced]( that its LPCN 1148 Phase 2 study in the treatment of patients with Cirrhosis met its primary endpoint. LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis. Dr. Mahesh Patel, President and CEO of Lipocine [stated](, "Managing cirrhosis is a significant unmet medical need with a strong pharmaco-economic rationale. We believe LPCN 1148 is a compelling development opportunity; if approved, we believe it has potential to be the standard of care in managing advanced cirrhosis." The stock is up over 40% after the release of the results. The $5.80 area was resistance and now becomes potential support. Above it, targets to the upside are $6.15 and then the pre-market high at $6.25. Beyond that, $7 and $8 come into play. Below $5.80, there is potential support at $5.50, $5.10, $4.90 and a gap to fill at $4.30. MNK - Closed up 186% after sources said company considering bankruptcy as part of plan to avoid paying money it owes to opioid victims Mallinckrodt (MNK) develops, manufactures, markets and distributes specialty pharmaceutical products and therapies in the US and internationally. Yesterday,[news circulated that the Wall St Journal reported](that sources said MNK was considering bankruptcy as part of a plan to avoid paying money it owes to opioid victims. The stock closed up 186% higher on the news and is gapping 16% higher this morning. The stock was down over 90% this year on fears that liabilities relating to the opioid crisis would wipe out shareholders. The news that a potential bankruptcy could avoid some of these liabilities and leave some shareholders value available post bankruptcy sent the stock soaring. There should be plenty of volatility for active traders this morning. The $1.50 area will be an important level to watch having averted both as resistance and support yesterday and in the after-hours. Above it, targets to the upside are $1.70 and then the after-hours high of $1.88. Beyond that, $2, $2.50 and $3.50 come into play. Below $1.50, there is potential support at $1.32, $1.10, $1 and then $0.72. META - Up 8% in pre after beating earnings estimates and growing ad revenue Meta Platforms (META) engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. The company owns Facebook, Whatsapp, Instagram and Meta brands. META [reported]( Q2 EPS of $2.98 vs $2.91 expected. Revenue for the quarter came in at $32 billion vs $31.08 billion expected. META guided Q3 2023 revenue of $32-34.5 billion, versus $31.2 billion expected. Ad revenue rose by 12%, faster than rival Google. The $325 area was resistance in the after-hours and in the pre-market marking the high post earnings. Above it, targets to the upside are $330, $335, $340 and $350. Below $325, there is potential support at $322, $320, $315, $310 with a gap to fill at $298.57. [Economic Calendar]( To Your Success! *Please see disclosures below.   Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull  DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. [RagingBull.com](, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States